ArticleFrontiers in oncology2026
AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death in China, characterized by insidious onset and poor prognosis. Most patients are diagnosed at intermediate-advanced stages with unresectable HCC (uHCC), and the combination of transarterial chemoembolization (TACE) with targeted and immunotherapy has shown promising efficacy. This study aimed to develop a prognostic tool for uHCC patients receiving TACE combined with sintilimab and bevacizumab therapy. Methods: A total of 176 uHCC patients from two institutions (March 2021 to May 2024) were included. Univariate and multivariate Cox regression identified alpha-fetoprotein (AFP), alkaline phosphatase (ALP), and tumor burden score (TBS) as independent predictors of overall survival (OS), based on which the AAT score model was constructed. The area under the receiver operating characteristic (ROC) curve in training and validation cohorts was calculated, and Kaplan-Meier analyses were performed to evaluate the model. Results: Cox regression confirmed AFP, ALP, and TBS as independent OS predictors, with the AAT model achieving areas under the ROC curve of 0.813 and 0.819 in training and validation cohorts, outperforming individual factors. Kaplan-Meier analysis of OS and progression-free survival (PFS) demonstrated that the AAT score could significantly stratify patients into low (≤1.8), median (>1.8 to ≤3.0), and high (>3.0) risk groups, with distinct 2-year OS rates of 80.0%, 48.0%, and 4.0%, and PFS rates of 63.3%, 56.0%, and 4.0% in the training cohort, validated in the cohort. Conclusions: The AAT model effectively stratifies OS and PFS in uHCC patients undergoing TACE plus sintilimab and bevacizumab, guiding personalized treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.